Search Results (1 to 10 of 3014 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 852 Journal of Medical Internet Research
- 543 JMIR Research Protocols
- 308 JMIR Formative Research
- 257 JMIR mHealth and uHealth
- 135 JMIR Public Health and Surveillance
- 117 Online Journal of Public Health Informatics
- 107 JMIR Mental Health
- 94 JMIR Medical Informatics
- 79 JMIR Dermatology
- 72 JMIR Human Factors
- 59 JMIR Cancer
- 48 JMIR Pediatrics and Parenting
- 47 JMIR Medical Education
- 44 JMIR Serious Games
- 38 JMIR Aging
- 29 Interactive Journal of Medical Research
- 29 JMIR Perioperative Medicine
- 26 JMIR Diabetes
- 22 JMIR Rehabilitation and Assistive Technologies
- 19 JMIR Cardio
- 18 Iproceedings
- 15 JMIR Infodemiology
- 10 JMIR AI
- 10 JMIRx Med
- 10 Journal of Participatory Medicine
- 9 JMIR Nursing
- 7 JMIR Bioinformatics and Biotechnology
- 4 JMIR Biomedical Engineering
- 2 Asian/Pacific Island Nursing Journal
- 2 Medicine 2.0
- 1 JMIR Neurotechnology
- 1 JMIR XR and Spatial Computing (JMXR)
- 0 iProceedings
- 0 JMIR Preprints
- 0 JMIR Challenges
- 0 JMIR Data
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
Go back to the top of the page Skip and go to footer section
(C) Private LLMs: EHR data can be shared with a local hospital LLM, and prompt entry with question curation can be used to gain oncologic insights. EHR: electronic health record.
This study was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (no. 22‐00347). Informed consent was waived given the retrospective nature of the study. To ensure confidentiality of patient data, only authorized research study personnel were permitted access to patient data.
JMIR Form Res 2025;9:e64544
Download Citation: END BibTex RIS
deal: samen werken aan duurzame zorg [Article in Dutch](https://www.rvo.nl/sites/default/files/2024-12/C-
J Med Internet Res 2025;27:e67538
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Several recent Canadian population-based studies have shown that many patients at high CVD risk continue to have low-density lipoprotein cholesterol (LDL-C) levels well above the guideline targets [2,3]. LDL-C has been extensively studied and described as a causal factor for CVD [4]. LDL-C levels above the target can result from multiple factors such as insufficient LDL-C lowering with statins, statin-related side effects, suboptimal medication adherence, and treatment inertia [5].
JMIR Cardio 2025;9:e58124
Download Citation: END BibTex RIS